Tazobactum%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520piperacillin

# Piperacillin-Tazobactam ## Overview Piperacillin-tazobactam is a combination antibiotic consisting of a penicillin-class antibacterial (piperacillin) and a beta-lactamase inhibitor (tazobactam). It is active against a broad spectrum of gram-positive, gram-negative, and anaerobic bacteria. ## Primary Indications * Complicated intra-abdominal infections * Complicated skin and skin-structure infections * Community-acquired pneumonia * Nosocomial pneumonia * Febrile neutropenia (empiric treatment) ## Adult Dosing Standard adult dose is 3.375 grams every 6 hours or 4.5 grams every 6 or 8 hours, administered intravenously over at least 30 minutes. Dosing frequency and duration depend on the indication, severity of infection, and patient response. * **Complicated Intra-abdominal Infections:** 3.375 g IV every 6 hours or 4.5 g IV every 8 hours. * **Complicated Skin and Skin-Structure Infections:** 3.375 g IV every 6 hours. * **Community-Acquired Pneumonia:** 3.375 g IV every 6 hours. * **Nosocomial Pneumonia:** 3.375 g IV every 6 hours or 4.5 g IV every 8 hours. * **Febrile Neutropenia:** 4.5 g IV every 6 or 8 hours. Maximum daily dose: 18 g (based on piperacillin component) for severe infections or those with significant beta-lactamase producing organisms. ## Pediatric Dosing Dosing is based on the piperacillin component: * **Children < 12 years:** 80 mg/kg/day of piperacillin (equivalent to 100 mg/kg/day of piperacillin-tazobactam) divided into 4 doses, administered IV. Maximum dose: 300 mg/kg/day of piperacillin (not to exceed 16 g/day of piperacillin). * **Children ≥ 12 years:** Same as adult dosing. Specific dosing for febrile neutropenia in pediatric patients may vary based on institutional protocols. ## Dose Adjustments * **Renal Impairment (CrCl ≤ 20 mL/min):** Reduce frequency. For 3.375 g dose: administer every 8 hours. For 4.5 g dose: administer every 12 hours. * **Renal Impairment (CrCl 21-50 mL/min):** For 3.375 g dose: administer every 6-8 hours. For 4.5 g dose: administer every 8-12 hours. * **Hemodialysis:** Administer dose after dialysis and supplement with an additional dose of 0.75 g. ## Contraindications * Known severe hypersensitivity to piperacillin, tazobactam, other penicillin antibiotics, or any component of the formulation. * History of allergic reactions to cephalosporins or carbapenems may increase the risk of cross-reactivity. ## Adverse Effects Common: Diarrhea, rash, nausea, vomiting, constipation, headache, insomnia, fever, phlebitis at the injection site. Serious: Anaphylaxis, C. difficile-associated diarrhea, seizures (especially with high doses or renal impairment), interstitial nephritis, Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatotoxicity, neutropenia, thrombocytopenia. ## Key Drug Interactions * **Probenecid:** May increase and prolong piperacillin-tazobactam plasma concentrations. * **Neuromuscular blocking agents (e.g., vecuronium):** Piperacillin may prolong the neuromuscular blockade. * **Warfarin:** Monitor INR closely as penicillins may decrease INR. * **Methotrexate:** Penicillins may decrease methotrexate clearance, potentially leading to toxicity. * **Bacteriostatic antibiotics:** May antagonize the effect of bactericidal agents like piperacillin-tazobactam. ## Monitoring * Monitor for signs and symptoms of hypersensitivity reactions. * Assess renal function (BUN, creatinine) and electrolytes, especially with prolonged use or in patients with renal impairment. * Monitor for signs of C. difficile-associated diarrhea. * Monitor complete blood count (CBC) for potential hematologic changes (neutropenia, thrombocytopenia). * Monitor liver function tests (LFTs). * Assess for clinical signs of infection resolution. ## Clinical Pearls * Tazobactam extends the spectrum of activity of piperacillin to include many beta-lactamase producing bacteria. * Administer IV over at least 30 minutes to minimize infusion-related reactions. * Reconstituted solution should be used within 24 hours when refrigerated or within 12 hours at room temperature. * Dosing in obese patients may require consideration of the piperacillin component. * The risk of seizures is higher in patients with renal impairment and those receiving higher doses. *** **Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making therapeutic decisions.